David Rosenstiel, MD
Otolaryngology · Tuscaloosa, ALNPI 1225069909
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $203 of the $264 with a category attached, or 76.8%. 8 manufacturers reported payments, led by Amgen at 31.8% of the total. 2025 is the largest year on record at $84, 2.1 times the $41 reported in 2019. That places this record below the midpoint for otolaryngology clinicians in AL, where the typical reported total is $1,585.
Across 12 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$84
- Sanofi$46
- Merck$38
- Aimmune Therapeutics, Inc.$27
- Aerin Medical Inc.$23
- Novartis$18
- plus $28 from 2 others
What the payments were for
- Food & beverage$20377%
- Education$6123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $84 |
| Sanofi | 2 | $46 |
| Merck | 2 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Aerin Medical Inc. | 1 | $23 |
| Novartis | 1 | $18 |
| Olympus America Inc. | 1 | $15 |
| Kaleo, Inc. | 1 | $12 |
How this compares
$264 in reported general payments places this provider in the 15th percentile of 155 otolaryngology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 18 | $91,627 |
| Fluticasone Propionate | 744 | $11,445 |
| Azelastine Hcl | 133 | $5,063 |
| Fluocinolone Acetonide Oil | 69 | $3,874 |
| Epinephrine | 12 | $3,230 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 20 | $2,986 |
| Omeprazole | 162 | $2,235 |
| Esomeprazole Magnesium | 14 | $2,036 |
| Famotidine | 98 | $1,246 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 63 | $905 |
| Ofloxacin | 24 | $759 |
| Levocetirizine Dihydrochloride | 53 | $569 |
| Ipratropium Bromide | 19 | $513 |
| Mometasone Furoate | 17 | $468 |
| Methylprednisolone | 70 | $465 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Tuscaloosa
- Gordon ShieldsTuscaloosa$3K
- Craig BenoitTuscaloosa$2K
- John DavisHoover$251K
- William McFeelyHuntsville$70K
- Michael SillersBirmingham$53K
- Justin TurnerBirmingham$34K
- Bradford WoodworthBirmingham$27K
- Patrick OwensBirmingham$26K
- Kirk WithrowBirmingham$22K
- Do-Yeon ChoBirmingham$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.